Comparative Study of Methylergometrine and Oxytocin in the PREVENTION of Primary Postpartum Haemorrhage
International Journal of Research and Reports in Gynaecology,
Background: Primary postpartum haemorrhage (PPPH) is a major cause of maternal mortality especially in low income countries. Reducing the likelihood of PPPH by routine active management of third stage of labour (AMSTL) can help reduce the maternal mortality associated with it.
Methodology: It was a randomized comparative study which compared the efficacy and safety of intramuscular methyl-ergometrine with intramuscular oxytocin in the third stage of labour. Four hundred and ninety two women undergoing normal vaginal delivery were recruited and randomized to group A and B with two hundred and forty six in each group. Group A received 0.2mg methyl-ergomertine intramuscularly and Group B received 10 i.u. oxytocin intramuscularly immediately after delivery of the baby. The efficacy and safety of these two drugs were analyzed based on percentage fall in haemoglobin (Hb) level, need for additional uterotonic agents, need for exploration and uterine evacuation, need for blood transfusion, duration of the third stage of labour, elevation of blood pressure, number of patients with retained placenta and the need for manual removal of placenta (MRP). All data were analyzed using the Statistical Package for Social Sciences (SSPS) version 16.
Results: Fall in haemoglobin, mean blood loss, duration of third stage of labour, need for additional uterotonics, and blood transfusion were significantly less in group A. There was significant difference (p 0.003) in the mean intra-partum blood loss between the methyl-ergometrine (166.4±92.0ml) and oxytocin (207.4±196.9ml) groups. However side effects like nausea, vomiting and rise in systolic and diastolic blood pressure were higher in women in group A. Only the diastolic blood pressure elevation was statistically significant (p < 0.0001).
Conclusion: Methyl-ergometrine is suggested to be superior to intramuscular oxytocin in controlling primary post-partum haemorrhage. Its use might be encouraged for the active management of the third stage of labour, especially in those without any contra-indication to its use.
- oxytocin; comparison
- primary postpartum haemorrhage
How to Cite
Say L, chou D, Gemmill A, Tuncalp O, Moller AB daniels JD, et al. Global causes of maternal: A WHO systematic Analysis Launcet Global Health. 2014;2(6):e323–e333.
Abouzahr C. Antepartum and postpartum haemorrhage. In: Murrray CJ, lopez AD, eds. Health Dimensions of sex and Reproduction. Boston, Mass: Harvard University Press. 1998;172–174.
International Confederation of Midwives (ICM), International Federation of Gynaecologists and Obstetricians (FIGO); Joint statement; management of the third stage of labour to prevent postpartum haemorrhage. J Obstet Gynaec Can. 2004; 26:1110–1112.
WHO, UNFPA, UNICEF, World Bank Group; Intergrated management of pregnancy and childbirth, postpartum and newborn care; A guide for essential practice; 2006.
Prendiville WJ, Harding JE, Elbourne DR, Stirrat GM. Active management of the third stage of labour comparison of oxytocin versus no uterotonics with outcome of PPH. Br J Obstet Gynae. 2000;107:1111 – 15
De Groot AN, Van Dongen PW, Vree TB, Hetster YA, Van Roosmalen J. Ergot alkaloids Current status and review of clinical pharmacology and therapeutic use compared with oxytocins in Obstetrics and Gynaecology. Drugs. 1998;56(4):523– 35.
Den Hertog CE, De Groot AN, Van Dongen PW. History and use of Oxytocics. Eur J Obstet Gynae ReprBio. 2001;94(1): 8 – 12.
Schuurmans N, Mackinnon C, Lane C, Etches D Prevention and management of postpartum haemorrhage; SOGC Clinical Practice Guidelines. J SOC Obstet Gynae. Can. 2000;22(4):271 – 281.
Scottish Programme for Clinical Effectiveness in Reproductive Health. Scottish Obstetric Guidelines and Audit project: The Management of postpartum haemorrhage; 1998.
Scottish Programme for Clinical Effectiveness in Reproductive Health. Scottish Obstetric Guidelines and Audit project: The Management of Postpartum Haemorrhage (Guidelines update); 2002.
WHO Department of Reproductive Health and Research. Vaginal bleeding after childbirth. WHO, UNFPA, UNICEF, World Bank, Editors, managing complications in pregnancy and childbirth; a guide for midwives and doctors. [WHO/RHR/007]. WHO integrated management of pregnancy and childbirth; 2002.
Goodman LS, Hardman JG, Limbird LE, Gilman AG. Goodman and Gilman’s. The pharmacological basis of therapeutics. 10th ed. New York: “Mc Graw – Hill; 2001.
Mc Cormick ML, Sanghvi HC, Kinzie B, Mclntosh N. Preventing postpartum haemorrhage in low – resource settings. Int J Gynae Obstet. 2002;77:267 – 75.
Prendiville WJ, Elbourne D, Mc Donald S. Active versus expectant management in the third stage of labour. Cochrane Database Systemic Rev. 2000(3): CD000007.
Boopathil A, Radhakrishnan Nayak S, Rao A, Rao B. Oxytocin versus methylergometrine in the active management of third stage of labour. Open J Obstet Gynae. 2014;4:666 – 671.
World Health Organisation. WHO recommendation for the preventing and treatment of postpartum haemorrhage; 2012.
Suman K De, Dhrubajyati S, Arnab KK, Apurba Saha, Tapan KG, Babul CD. A comparative study of Ergometrine and oxytocin in controlling third stage blood loss. A Randomised Control Trial. Sch J App Med. 2013;1(5):595-599.
Chukwuemeka O Ezeama, George U Eleje, Nkiru N. Anthony O Igwegbe and Joseph I Ikechebelu, Ahizechukwu C Eke. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labour. Int J Obstet Gynae. 2014;124(1):67 – 71.
Gohil JT, Tripathi B. A study to compare the efficacy of misoprostol, oxytocin, methyl-ergometrine and Ergometrine – oxytocin in reducing blood loss in inactive management of 3rd stage of labour. J Obstet Gynae India. 2011;61(4):408 – 412.
Abstract View: 89 times
PDF Download: 52 times